Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
This study has been completed.
Study NCT00430846 Information provided by Seattle Genetics, Inc.
First Received on February 1, 2007. Last Updated on June 6, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma, Large-Cell, Anaplastic
Additional conditions recognized in this trial
Lymphoma, Large B-Cell, Diffuse
More general conditions related to this trial
Immune System Diseases
Neoplasms by Histologic Type
Neoplasms by Site
Interventions listed in this trial
Sponsors listed in this trial
Seattle Genetics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers